Bisphosphonate‐enoxacin inhibit osteoclast formation and function by abrogating RANKL‐induced JNK signalling pathways during osteoporosis treatment
2019 ◽
Vol 509
(1)
◽
pp. 294-300
◽
2018 ◽
Vol 19
(9)
◽
pp. 2569
◽
Keyword(s):